Advertisement Pharmaceutical Business review - Page 49 of 5290 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
September 15, 2026

FDA reduces monitoring time for Amgen’s Imdelltra infusions

The US Food and Drug Administration (FDA) has approved an update to the prescribing information for Amgen’s Imdelltra (tarlatamab-dlle), reducing the recommended monitoring time for patients with extensive-stage small cell lung cancer (ES-SCLC) after their first two infusions.

Imdelltra is a targeted immunotherapy designed to bind to DLL3 proteins, activating the immune system to target SCLC cells. Credit: MY STOCKERS/Shutterstock.com.